TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Occurrence of Serious Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Safety/ Adverse Event Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy Outcome
Endpoint domain: Physiological/clinical
Primary endpoint: Change in the Cerebellar cognitive affective syndrome (CCAS) Scale From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient experience and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change in Eczema Area and Severity Index (EASI) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumonia count
Endpoint domain: Adverse events/effects
Primary endpoint: Upper limb motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients on medical or surgical treatment at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean number of medications required to control IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electron Transport Chain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indices of bone turnover and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical laboratory safety tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary block failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of ALT-803
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response Rate to Induction Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in leg muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Erythropoietin Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form 36 Health Survey Summary Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Pulmonary Arterial Pressure Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in fecal incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone Scan Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: All-cause readmission rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: All-cause reutilization rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: COPD development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: extended early bactericidal activity (EBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Achieve Lifestyle modification target
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in Total Corneal Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of endostatin in skin and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic recurrence based on Rutgeert scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in NP-related productivity loss
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Serum iPTH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of biochemical markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of basic parameters of visual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of supportive digital applications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Validation of the LIFE4LV questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in The Center for Epidemiologic Studies Depression Scale for Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of current guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life after CA
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Obstruction of 1st C-SEMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of jaundice at death
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: report of an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma concentration (Cmax) of gefapixant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of PCSK9 and FXR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DLPC levels in postprandial serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Premature Ovarian Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rates of COPD Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in wake time physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment parameters of Neutrophils and Platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transplant related mortality by Day 100
Endpoint domain: Mortality/survival
Primary endpoint: Proportion With Prescription Opioid Use Disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Framingham score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 7-year MACE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Periodontal health condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 3 Days of Product Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Product Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With One or More Unsolicited Non-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary nitrate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in estimated glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: tremor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ataxia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in weekly urticaria activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and percentage of participants with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of numeric rating scale (rest, movement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of femoral cartilage thickness via ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Nocturnal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tumor SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUV tumor-to-background ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correlation between SUV and the degree of immunohistochemical PSMA staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of occurrence of clinically significant device malposition
Endpoint domain: Adverse events/effects
Primary endpoint: Pneumococcal and meningococcal immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gait Knee Adduction Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cartilage Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct diagnosis percentage of FUO patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Total and Unbound DTG Concentrations Between CSF and Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Coma Recovery Scale revised score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to opioids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants reaching LDL-C goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Abdominal pressure urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with recurrent or refractory hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring secondary evacuation surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Glycoprotein-like DMBT1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in static neck strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dynamic neck strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 40 yard dash time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Disease Activity Score (DAS28 [ESR]) <= 3.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Average Joint Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sieving coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bulbar dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Navicular drop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subtalar angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity for diagnosing Alzheimer's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with Serious Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Near Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amsler Grid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BEARNI questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of women delivering before 7 days
Endpoint domain: Mortality/survival
Primary endpoint: Duration of rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good Functional Outcome as Defined by a Modified Rankin Score of 0-2
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of All Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Vaginal size for stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of pregnant women oriented to psychiatric follow-up
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reduction in Mean IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MARS-A scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in communication ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Participant Skin Conductance Responding (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Group Differences in Serum Brain-Derived Neurotrophic Factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Group Differences in Serum Endocannabinoid (eCB) Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Percent Dose Amounts Delivered by the Pump (Aggregate of Insulin and Glucagon)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin Area Under the Curve in the 3.5 Hours Following the Insulin Bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pressure center displacement speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-bleeding/Non-elective Hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: >10% Drop in Forced Vital Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Predictive Value of PET/CT imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in oxygen desaturation index (ODI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in time under 90% saturation (T90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 28-day Seizure Rate for All Primary Generalized Tonic-Clonic Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: craniofacial height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Mean Fluorescence Index (MFI) of Donor Specific Antibodies (DSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Repeatable Battery for the Assessment of Neuropsychological Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fractional Excretion of Endogenous Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to event/relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline lack of consistent current use of contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in current vaginal and anal sex without condom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on CGI-I Scale - ITT Population
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on CGI-I Scale - PP Population
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-cesarean endometritis
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with diastolic blood pressure <85 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to remission of signs and symptoms of active tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to negative measurement of mycobacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Penetration - Aspiration Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Swallowing outcomes
Primary endpoint: Safety evaluation based on adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Molecular remission status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in lung ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in concentration of HDL subfractions 2a and 2b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in concentration of LDL subfractions LDL-5 and LDL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fMRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With Nephrotoxic Medication Associated AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Failure of assigned non-invasive mode
Endpoint domain: Adverse events/effects
Primary endpoint: Change of the preoperative anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Growth Rate on Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference between Δp and Δm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients exceeding Hemoglobin (Hb) of 15 g/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with at least one complication classified higher or equal to grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Differentially Expressed Transcripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the receiver operating curve (AUC) of risk estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Therapeutic Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left ventricle diameter/volume/ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of adverse events at 1 month
Endpoint domain: Adverse events/effects
Primary endpoint: improvement of the hemodynamic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients desaturating below 93% in SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of severe adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Satisfaction Mean on a 0-10 Likert Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death or rehospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Serum Chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and Tolerability (number of adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of platelet response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Screened for All Conditions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective response rate of imatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of remission of patients with thymic carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of imatinib
Endpoint domain: Adverse events/effects
Primary endpoint: Change in iHOT Version 12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Patient Health Questionnaire 9 (PHQ-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal changes in mood outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TTTG value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: root coverage aesthetic score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Patients With Viral Loads < 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Spatial Span Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes